Assembly Biosciences Inc (ASMB)vsVertex Pharmaceuticals Inc (VRTX)
ASMB
Assembly Biosciences Inc
$29.80
-2.17%
HEALTHCARE · Cap: $606.75M
VRTX
Vertex Pharmaceuticals Inc
$519.51
+0.79%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 16718% more annual revenue ($12.59B vs $74.84M). VRTX leads profitability with a 35.0% profit margin vs -0.1%. ASMB trades at a lower P/E of 24.6x. VRTX earns a higher WallStSmart Score of 64/100 (C+).
ASMB
Avoid32
out of 100
Grade: F
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.8%
Fair Value
$41.32
Current Price
$29.80
$11.52 discount
Margin of Safety
+46.5%
Fair Value
$963.47
Current Price
$519.51
$443.96 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 38.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -0.0% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ASMB
The strongest argument for ASMB centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 38.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ASMB
The primary concerns for ASMB are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ASMB profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
ASMB carries more volatility with a beta of 1.13 — expect wider price swings.
ASMB is growing revenue faster at 38.9% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 32/100), backed by strong 35.0% margins and 12.5% revenue growth. ASMB offers better value entry with a 33.8% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Assembly Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?